Targeted therapy for hepatocellular carcinoma
Fudan University · Zhongshan Hospital · +2 more institutions
Abstract
The last 3 years have seen the emergence of promising targeted therapies for the treatment of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a decade and newer modalities were ineffective and did not confer any increased therapeutic benefit until the introduction of lenvatinib which was approved based on its non-inferiority to sorafenib. The subsequent success of regorafenib in HCC patients who progress on sorafenib treatment heralded a new era of second-line treatment and was quickly followed by ramucirumab, cabozantinib, and the most influential, immune checkpoint inhibitors (ICIs). Over the same period combination therapies, including anti-angiogenesis agents with ICIs,…
Citation impact
- FWCI
- 50.28
- Percentile
- 100%
- References
- 237
Authors
5- AHAo HuangCorresponding
Fudan University, Zhongshan Hospital
- XYXin‐Rong Yang
Fudan University, Zhongshan Hospital
- WYWen Yuan Chung
University Hospitals of Leicester NHS Trust
- ARAshley R. Dennison
University Hospitals of Leicester NHS Trust
- JZJian Zhou
Fudan University, Zhongshan Hospital, Ministry of Education
Topics & keywords
- Sorafenib
- Lenvatinib
- Regorafenib
- Cabozantinib
- Medicine
- Ramucirumab
- Hepatocellular carcinoma
- Targeted therapy
- Good health and well-being
Funding
- SMShanghai Municipal Health CommissionAward: 2019CXJQ02
- NNNational Natural Science Foundation of ChinaAwards: 81772578, 81830102, 81802991, 2019CXJQ02, 2019YFC1315802, 2019YFC1315800
- SAScience and Technology Commission of Shanghai MunicipalityAward: 19441905000
- NKNational Key Research and Development Program of ChinaAwards: 81830102, 2019YFC1315800, 2019YFC1315800, 2019YFC1315802, 2019YFC1315802, 2019CXJQ02, 2016YFF0101405